Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot ...

主要风险是， 如果FDA禁止复合GLP-1复合药物的新闻导致股价下跌，即使Hims & Hers Health准确地表示其个性化服务对业务的影响有限，市场也可能轻易忽视其强劲的核心业务， 直到在线健康平台证明GLP-1复合药物业务并非 驱动力 ...

根据向美国证券交易委员会提交的Form 4文件显示，Hims & Hers Health, Inc.（NYSE:HIMS）的首席执行官Andrew Dudum最近进行了一系列股票交易。在1月21日和22日，Dudum以30.00美元至30.0781美元的价格出售了总计14,569股A类普通股，交易总额为438,184美元。

Hims & Hers Health (NYSE: HIMS) is a relatively young company addressing age-old healthcare challenges by offering ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 69.2 ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...